Brandi, Giovanni <br/><br/>
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.  [electronic resource] 

 -  Pancreas  Jan 2014 
 - 53-63 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1536-4828 
<br/><br/><label>Standard No.: </label>10.1097/MPA.0b013e3182a6486e  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Blotting, Western<br/>Cell Line<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Deoxycytidine--administration & dosage<br/>Down-Regulation--drug effects<br/>Drug Evaluation, Preclinical--methods<br/>Enzyme Activation--drug effects<br/>Extracellular Signal-Regulated MAP Kinases--metabolism<br/>Gabexate--administration & dosage<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Interleukin-8--genetics<br/>Matrix Metalloproteinase 2--genetics<br/>Matrix Metalloproteinase 9--genetics<br/>NF-kappa B--antagonists & inhibitors<br/>Pancreatic Neoplasms--drug therapy<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Serine Proteinase Inhibitors--administration & dosage<br/>Vascular Endothelial Growth Factor A--genetics<br/>Gemcitabine